Mechanistic Target of Rapamycin Pathway in Epileptic Disorders

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• The mechanistic target of rapamycin (mTOR) pathway regulates cellular metabolism and is crucial for neural development and neurodegeneration.
• Germline and somatic mutations in mTOR pathway genes are implicated in various epileptic disorders.
• Hyperactivation of the mTOR pathway is increasingly recognized as a cause of epilepsy, particularly intractable focal epilepsy due to somatic mutations.

Purpose of the Study:

• To review recent advances in understanding mTOR signaling in epilepsy.
• To focus on the development and limitations of mTOR-targeting therapies for epileptic seizures.
• To discuss future perspectives on mTOR inhibition and diagnostic methods for somatic mutation-related epilepsies.

Main Methods:

• Review of current literature on mTOR pathway genetics and signaling in epilepsy.
• Analysis of epilepsy models with aberrant mTOR activation.
• Examination of therapeutic strategies targeting the mTOR pathway.

Main Results:

• Somatic mutations in the mTOR pathway are a significant genetic cause of intractable focal epilepsy, such as focal cortical dysplasia.
• Epilepsy models demonstrate the role of mTOR pathway hyperactivation in epileptogenesis.
• Evidence suggests mTOR inhibitors may be effective for treating epilepsies associated with mTOR pathway gene mutations.

Conclusions:

• Understanding mTOR signaling is critical for epilepsy research.
• mTOR inhibitors represent a potential therapeutic avenue for specific epilepsy types.
• Further research is needed on diagnostic methods and optimizing mTOR inhibition therapies for brain somatic mutation-induced epilepsies.